IQVIA Tops Q2 Forecasts and Lifts Full-Year Outlook on Record R&D Bookings

summarizeSummary

IQVIA posted Q2 2026 revenue of $4.37 billion and Adjusted Diluted EPS of $3.15, both above the high end of guidance, and raised its full-year outlook. R&D net new bookings hit a record $3.15 billion, up 19% year-over-year.

check_boxKey Events · Earnings and Guidance · IQV

• Q2 Revenue and EPS Beat

  Revenue of $4,368 million grew 8.7% year-over-year, and Adjusted Diluted EPS of $3.15 rose 12.1%, exceeding the high end of management's expectations.

• Record R&D Bookings

  R&D Solutions net new bookings reached $3.15 billion, a 19% increase year-over-year, yielding a 1.22x book-to-bill ratio and a contracted backlog of $34.2 billion.

• Full-Year Guidance Raised

  Management lifted 2026 guidance: revenue to $17,275–$17,475 million (midpoint growth 6.5% vs. prior 5.8%), Adjusted EBITDA to $4,000–$4,050 million, and Adjusted Diluted EPS to $12.80–$13.00.

• Share Repurchases Continue

  The company repurchased $398 million of stock in Q2, bringing first-half repurchases to $950 million; $2,819 million remains under the board-authorized program.

auto_awesomeAnalysis · IQV · Industrial Applications And Services

A strong second quarter saw IQVIA exceed the top end of its own projections for revenue, Adjusted EBITDA, and Adjusted Diluted EPS. The highlight is R&D Solutions net new bookings of $3.15 billion — a 19% surge and a 1.22x book-to-bill ratio — pointing to robust demand and an expanding backlog that underpins sustained revenue growth. Reflecting higher organic growth and M&A contributions, management raised full-year guidance, pushing the revenue growth midpoint to 6.5% from 5.8%. During the quarter the company also repurchased $398 million in stock, bringing the first-half total to $950 million, with $2.8 billion remaining under its authorization. This mix of operational outperformance, a record bookings pipeline, and aggressive capital return underscores confidence in the business trajectory.